Inthera Bioscience is an emerging Swiss biotechnology company that develops innovative and highly effective therapies against currently incurable cancers. The company is tackling “undruggable” targets with innovative chemistry for the design of small molecule inhibitors of intracellular protein-protein interactions. The most advanced of these first-in-class therapeutics, a modulator of dysregulated transcription, is currently progressing towards clinical stage.
Total raised: $16.382668M
Investors 2
Date | Name | Website |
08.11.2022 | M Ventures | m-ventures... |
- | Aglaia Onc... | aglaia-onc... |
Funding Rounds 2
Date | Series | Amount | Investors | Deal News |
26.06.2018 | Series A | $5.475277M | - | startuptic... |
31.05.2017 | Series A | $10.907391... | - | finsmes.co... |
Mentions in press and media 6
Date | Title | Description | Source |
26.06.2018 | Inthera Bioscience Raises €4.7M Second Tranche of €9.6M Seri... | Inthera Bioscience AG, a Wädenswil, Switzerland-based pre-clinical stage oncology company targeting ... | finsmes.co... |
26.06.2018 | Inthera Bioscience secures €4.7 million in series A financin... | Inthera Bioscience is a biopharmaceitical company developing first-in-class targeted small molecul... | startuptic... |
02.06.2017 | Inthera Bioscience Raises CHF 10.5 Million in Series A Finan... | The financing round was led by Merck Ventures, with equal contribution from Aglaia BioMedical Vent... | startuptic... |
31.05.2017 | Inthera Bioscience Raises CHF10.5M in Series A Financing Rou... | Inthera Bioscience, a Zurich, Switzerland-based biopharmaceutical company developing targeted small ... | finsmes.co... |
15.12.2015 | Inthera Bioscience Raises $3.7M in Seed Funding | Inthera Bioscience, a Zürich, Switzerland-based biopharmaceutical company focused on the development... | finsmes.co... |
14.12.2015 | Inthera Bioscience raises EUR 3.4 million in seed financing ... | Inthera Bioscience is focused on developing inhibitors of intracellular protein-protein interactio... | startuptic... |